Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

531
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
531
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

414
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
414
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

744
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
744
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

508
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
508
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

627
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
627

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hazards and complications of dialysis.

The New England journal of medicine·2011
Same author

Encephalomyeloradiculitis (Guillain-Barré syndrome) as a complication of infectious hepatitis.

Annals of internal medicine·2010
Same author

Infectious hepatitis; clinical and laboratory features of 295 cases.

The American journal of the medical sciences·2010
Same author

Drug- and chemical-induced cholestasis.

Clinics in liver disease·2001
Same author

Drug-induced liver disease.

Clinics in liver disease·2001
Same author

Management of drug-induced liver disease.

Current gastroenterology reports·2001
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.1K

Captopril-associated cholestatic jaundice.

J Rahmat, R L Gelfand, M C Gelfand

    Annals of Internal Medicine
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Captopril, an angiotensin-converting enzyme inhibitor, can cause idiosyncratic cholestatic jaundice. This rare hepatic injury presents with prominent cholestatic features, highlighting a potential side effect of this hypertension medication.

    More Related Videos

    Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
    06:35

    Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice

    Published on: June 28, 2021

    4.5K
    Creation of Reversible Cholestatic Rat Model
    09:39

    Creation of Reversible Cholestatic Rat Model

    Published on: May 22, 2011

    15.4K

    Related Experiment Videos

    Last Updated: Jan 10, 2026

    Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
    10:15

    Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

    Published on: November 10, 2021

    2.1K
    Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
    06:35

    Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice

    Published on: June 28, 2021

    4.5K
    Creation of Reversible Cholestatic Rat Model
    09:39

    Creation of Reversible Cholestatic Rat Model

    Published on: May 22, 2011

    15.4K

    Area of Science:

    • Pharmacology
    • Hepatology
    • Internal Medicine

    Background:

    • Captopril is a widely used angiotensin-converting enzyme (ACE) inhibitor for managing difficult hypertension.
    • While ACE inhibitors have known side effects, hepatic injury is infrequently reported with captopril.
    • This study investigates the occurrence and characteristics of liver injury associated with captopril use.

    Observation:

    • A case of cholestatic jaundice was observed in a patient treated with captopril.
    • A review of drug manufacturer data and medical literature identified 13 additional cases of hepatic injury linked to captopril.
    • The observed hepatic injuries predominantly exhibited cholestatic or mixed cholestatic-hepatocellular patterns.

    Findings:

    • Captopril-associated jaundice appears to be an idiosyncratic adverse effect.
    • The characteristic presentation of captopril-induced liver injury includes significant cholestatic features.
    • This suggests a specific mechanism of liver damage related to captopril's pharmacological action.

    Implications:

    • Clinicians should be aware of the potential for captopril to cause cholestatic jaundice, even if rare.
    • Prompt recognition and management of this adverse effect are crucial for patient outcomes.
    • Further research may elucidate the specific mechanisms underlying captopril-induced cholestatic injury.